Turnover Rate at 1.9% and Average Salary Over 100 Million Won at Samsung Biologics... Is There Justification for the Union's Industrial Action?
Turnover Rate at 1.9% Last Year
Lowest in the Industry
As the Samsung Biologics labor union continues its compliance action following a first strike, demanding improvements in wages and working conditions, some point out that the union's justification for its struggle is weakening. This is due to the fact that objective indicators reflecting the company’s employment stability and compensation levels are among the highest in the industry.
According to the ESG (Environmental, Social, and Governance) report released by Samsung Biologics on June 1, the company's total employee turnover rate stood at 1.9% as of last year. Since recording a turnover rate of 4.5% in 2021, the rate has continued to decrease—falling to 4.0% in 2022, 3.4% in 2023, and 2.7% in 2024—entering the 1% range for the first time last year. The pharmaceutical and biotech industry is generally categorized as one with high demand for specialized talent in areas such as research and development, manufacturing, quality control, and regulatory affairs, making employee movement between companies very active.
In fact, a comparison with major competitors further highlights the significance of Samsung Biologics' figure. As of 2024, the turnover rate at leading bio companies is around 10%, while traditional pharmaceutical companies record rates in the double digits. Given these industry characteristics, a 1.9% turnover rate is extraordinary, indicating that it is difficult for employees to find alternative positions within the sector that offer better working environments or compensation.
This exceptionally low turnover rate is mainly attributed to a highly competitive compensation system. According to the business report disclosed on the Financial Supervisory Service’s DART system, the average compensation per Samsung Biologics employee last year was 114 million won. This represents approximately a 44% increase over four years, compared to the 79 million won average compensation in 2021, with an annual average increase rate of 10%.
Even compared to the compensation growth trends at other major industry players during the same period, Samsung Biologics stands out. Celltrion’s average compensation rose from 78 million won in 2021 to 107 million won in 2025, while Yuhan Corporation increased from 89 million won to 100 million won. SK Bioscience maintained its average at around 68 million won. Notably, Samsung Biologics is a relatively young organization, with the average age of all employees being around 30. Taking this into account, the actual salary level experienced by employees in their twenties and thirties is considered to rank among the highest not only in the pharmaceutical and biotech industry but also among major conglomerates in Korea.
With objective data confirming the industry’s lowest turnover rate and highest compensation, public perception of the union’s industrial action is divided. Some analysts argue that continuing a labor struggle that could potentially disrupt the operation of critical bio-production lines in the global pharmaceutical supply chain is unlikely to gain social support, given the stable work environment with minimal employee attrition.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An industry insider commented, “Given the frequent personnel movement characteristic of this industry, a 1.9% turnover rate is clear evidence of employee satisfaction. Industrial action in a situation where the average annual salary exceeds 100 million won may not resonate with the general public.” Another source expressed concern, saying, “Since customer trust is paramount in the contract development and manufacturing organization (CDMO) business, the risk of production disruption due to escalating labor-management conflict could harm the company’s external reputation.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.